 |
Clinical Trial Questions?
|
|
|
Phase III Randomized Study of Valacyclovir for Prevention of Serious Fungal and Bacterial Infections in Cytomegalovirus (CMV)-Negative Patients Receiving a CMV-Positive Allogeneic Stem Cell Transplantation
Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information
Registry Information
Alternate Title
Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are
Undergoing Donor Stem Cell Transplantation
Basic Trial Information
| Phase | Type | Status | Age | Protocol IDs |
|---|
| Phase III | Supportive care | Completed | 12 and over | FHCRC-1603.00
NCI-H02-0092, NCT00045292 |
Objectives - Compare the occurrence of serious invasive fungal or bacterial infections during the first 270 days after transplantation in cytomegalovirus (CMV)-negative patients receiving a CMV-positive allogeneic stem cell transplantation and valacyclovir or placebo.
- Compare the occurrence of primary CMV infection within the first 100 days after transplantation in patients treated with these regimens.
- Compare the survival of these patients at 100 days and 270 days post-transplantation.
- Compare the occurrence of CMV disease at day 100 and day 270 post-transplantation in patients treated with these regimens.
- Compare the safety of these regimens in these patients.
- Correlate the presence of CMV in stem cell product with post-transplantation CMV infection in these patients.
- Determine if subclinical CMV infection results in a virus-specific immune response (humoral and cellular) in these patients.
- Compare the quality of life of patients treated with these regimens.
- Compare resource utilization (e.g., rates of hospitalization, number of days alive out of the hospital, days in the intensive care unit, days on mechanical ventilation, use of antimicrobials and filgrastim [G-CSF], and number of invasive procedures) in patients treated with these regimens.
Entry Criteria Disease Characteristics:
- Disease requiring one of the following types of stem cell transplantation:
- First myeloablative allogeneic peripheral blood stem cell
- Unrelated cord blood
- Bone marrow
- Related or unrelated donor
- T-cell depleted or non-T-cell depleted
- CD34 selected or non-selected
- Patient must be cytomegalovirus (CMV)-seronegative and donor must be
CMV-seropositive
- No transplantation with nonmyeloablative regimens, including any of the following:
- Fludarabine and total body irradiation (TBI) (2 Gy or less)
- TBI alone (2 Gy)
- Fludarabine, cytarabine, and idarubicin
- Fludarabine and melphalan (140 mg/m2 or less)
- No definite or probable pre-transplantation diagnosis of invasive mold
infection (aspergillosis, fusariosis, or zygomycosis), including pulmonary or
hepatic nodules consistent with invasive mold infection for which patients
are receiving targeted prophylaxis with amphotericin or other mold-active
products
- No pre-transplantation-CMV disease (gastrointestinal or pneumonia)
Prior/Concurrent Therapy:
Biologic therapy - See Disease Characteristics
Chemotherapy - See Disease Characteristics
Endocrine therapy Radiotherapy - See Disease Characteristics
Surgery Patient Characteristics:
Age Performance status Life expectancy Hematopoietic Hepatic Renal Other - HIV negative
- No hypersensitivity to acyclovir or valacyclovir
- Not pregnant
- Fertile patients must use effective contraception
Expected Enrollment A total of 115-230 patients (58-115 per treatment arm) will be accrued for this study within 2 years. Outline This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to participating center and type of transplantation (matched related vs mismatched/unrelated). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oral valacyclovir 4 times daily beginning with transplantation conditioning (usually day -5) and continuing until day 100 after transplantation. Patients receive high-dose acyclovir, instead of valacyclovir, IV every 8 hours beginning on day -1 and continuing until oral medications are tolerated. Allogeneic stem cells are infused on day 0.
- Arm II: Patients receive oral or IV placebo on the same schedule as in arm I.
Quality of life is assessed at baseline and on days 50 and 100.
Patients are followed every 2 weeks for 6 months.
Trial Contact Information
Trial Lead Organizations Fred Hutchinson Cancer Research Center | | | | Garrett Nichols, MD, MSC, Protocol chair | | | |
| Registry Information | | | Official Title | | A Phase III Multicenter Study of Cytomegalovirus Prophylaxis with Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants | | | Trial Start Date | | 2002-04-04 | | | Trial Completion Date | | 2004-10-06 | | | Registered in ClinicalTrials.gov | | NCT00045292 | | | Date Submitted to PDQ | | 2002-06-26 | | | Information Last Verified | | 2009-03-30 | | | NCI Grant/Contract Number | | CA18029, CA15704, AI01839 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.  Back to Top |
|
